HTB

Cochrane review of HCV treatment misses real issues of access to care

cochrane graphic

Simon Collins, HIV i-Base

Although the Cochrane review process is designed to minimise subjective assessments and bias from studies, setting the initial questions is highly subjective.

And if the review asks a question that is not appropriately matched, the results are likely to be nonsense.

A recent Cochrane review of new hepatitis C (HCV) drugs has discredited what can be a useful process for combining results from multiple studies. Of more concern, irresponsible reporting of the review by mainstream media risks limiting access to effective treatment.

The original review was published online on 6 June 2017. [1]

It asked what appears to be a reasonable question: whether new HCV drugs prevent liver-related serious health complications including mortality. It then reviewed 168 research studies of multiple new HCV drugs – called direct acting antivirals (DAAs) – and reported a lack of evidence showing benefits.

Importantly, the lack of evidence is very different from a lack of effect.

DAAs are in fact so effective that they cure nearly everyone within 8 to 24 weeks. This means HCV studies are short-term even if extended follow-up continues for longer. But the serious liver-related complications used as endpoints in the review are generally long-term events, with risk accumulating over years and sometimes decades.

DAA studies are much too short-term to see these endpoints, so there is not enough evidence to prove benefit on these criteria. DAA studies are usually either:

  1. In people who are generally healthy, so very few events will happen in either arm over a short study; or
  2. In people with very advanced liver disease when both groups are similarly likely to have higher rates of complications because long-term damage is already significant and difficult to reverse.

In either of these situations, there are likely to be few differences between active vs control groups.

Further reporting by mainstream media of the top-level results without critically reviewing the study, included an article by the health editor in the Guardian, that is even more unhelpful than the original review. [2]

In the spirit of irresponsible and alarmist journalism that is unfortunately common when looking to make headlines rather than explain science, the story in the Guardian is instead likely to cause harm:

  • It could destablilise access to highly effective treatment that is already controversial because of the unnecessarily high price charged for these medicines.
  • It could dissuade people from testing for HCV and accessing treatment.
  • It could be used by the NHS and other health providers to block or delay commissioning of this effective treatment.

Comment

Using the Cochrane review to manipulate essential issues over access to highly effective medicines is dangerous and irresponsible. It also questions whether a peer-review process should pick up methodological weaknesses for these reviews.

News media – including community press – needs to critically access scientific studies before treating health stories as news that can be spun for a headline.

Instead, the mainstream media could have found ways to explain how scientific approaches were being distorted. A similar Cochrane approach to smoking cessation programmes would find a similar lack of evidence for health: these short programmes wouldn’t see different rates of lung cancer in each group, but no-one would be stupid enough now to question the clear benefits from quitting.

HCV drugs are currently shockingly over-priced and cost is limiting access to many people who need them – both in the UK and globally. This challenges their cost-effectiveness in different settings but not their effectiveness.

Access to DAAs for people with HIV/HCV coinfection is becoming steadily easier. This is covered in detail in a new i-Base guide to coinfection – available in print and online. As with all i-Base resources, this comprehensive easy-to-read guide is available free, including in bulk for UK clinics. [3]

References

  1. Jakobsen JC at al. Direct-acting antivirals for chronic hepatitis C. Cochrane review (6 June 2017). DOI: 10.1002/14651858.CD012143.pub2
    http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012143.pub2/full
  2. Bosley S. ‘Miracle’ hepatitis C drugs costing £30k per patient ‘may have no clinical effect’. The Guardian. (13 June 2017).
    https://www.theguardian.com/society/2017/jun/08/miracle-hepatitis-c-drugs-costing-30k-per-patient-may-have-no-clinical-effect
  3. HIV i-Base. Hepatitis C for people living with HIV. (June 2017)
    http://i-base.info/guides/hepc

Links to other websites are current at date of posting but not maintained.